Regeneron Pharmaceuticals Inc Beats Roche Holding Ltd. The Race For Diabetes-Related Eye Disease Drugs

February 19, 2015 11:43 AM

15 0

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) emerged victorious over Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) after its blockbuster drug Eylea proved to be better than Roche’s Lucentis and Avastin in treating severe diabetes-related eye diseases, in the first head-to-head clinical study comparing the two companies’ treatments.

The results come as a major breakthrough for Regeneron and may boost the company’s sales significantly for 2015 and beyond. Eylea, which is the company’s top-selling drug, generating almost 67% of the total company revenue, was initially approved by the US Food and Drug Administration in 2011 for tr...

Read more

To category page